Literature DB >> 18006816

Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types.

Eric S Martin1, Giovanni Tonon, Raktim Sinha, Yonghong Xiao, Bin Feng, Alec C Kimmelman, Alexei Protopopov, Elena Ivanova, Cameron Brennan, Kate Montgomery, Raju Kucherlapati, Gerald Bailey, Mark Redston, Lynda Chin, Ronald A DePinho.   

Abstract

Colorectal cancer (CRC) is a major cause of cancer morbidity and mortality, and elucidation of its underlying genetics has advanced diagnostic screening, early detection, and treatment. Because CRC genomes are characterized by numerous non-random chromosomal structural alterations, we sought to delimit regions of recurrent amplifications and deletions in a collection of 42 primary specimens and 37 tumor cell lines derived from chromosomal instability neoplasia and microsatellite instability neoplasia CRC subtypes and to compare the pattern of genomic aberrations in CRC with those in other cancers. Application of oligomer-based array-comparative genome hybridization and custom analytic tools identified 50 minimal common regions (MCRs) of copy number alterations, 28 amplifications, and 22 deletions. Fifteen were highly recurrent and focal (<12 genes) MCRs, five of them harboring known CRC genes including EGFR and MYC with the remaining 10 containing a total of 65 resident genes with established links to cancer. Furthermore, comparisons of these delimited genomic profiles revealed that 22 of the 50 CRC MCRs are also present in lung cancer, glioblastoma, and/or multiple myeloma. Among 22 shared MCRs, nine do not contain genes previously shown genetically altered in cancer, whereas the remaining 13 harbor 35 known cancer genes, of which only 14 have been linked to CRC pathogenesis. Together, these observations point to the existence of many yet-to-be discovered cancer genes driving CRC development, as well as other human cancers, and show the utility of high-resolution copy number analysis in the identification of genetic events common and specific to the development of various tumor types.

Entities:  

Mesh:

Year:  2007        PMID: 18006816     DOI: 10.1158/0008-5472.CAN-07-2742

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas.

Authors:  Hongwu Zheng; Haoqiang Ying; Ruprecht Wiedemeyer; Haiyan Yan; Steven N Quayle; Elena V Ivanova; Ji-Hye Paik; Hailei Zhang; Yonghong Xiao; Samuel R Perry; Jian Hu; Anant Vinjamoori; Boyi Gan; Ergun Sahin; Milan G Chheda; Cameron Brennan; Y Alan Wang; William C Hahn; Lynda Chin; Ronald A DePinho
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

2.  Integrated genomic profiling identifies microRNA-92a regulation of IQGAP2 in locally advanced rectal cancer.

Authors:  Raphael Pelossof; Oliver S Chow; Lauren Fairchild; J Joshua Smith; Manu Setty; Chin-Tung Chen; Zhenbin Chen; Fumiko Egawa; Karin Avila; Christina S Leslie; Julio Garcia-Aguilar
Journal:  Genes Chromosomes Cancer       Date:  2016-04       Impact factor: 5.006

Review 3.  Molecular basis of the potential of mesalazine to prevent colorectal cancer.

Authors:  Carmine Stolfi; Roberto Pellegrini; Eleonora Franze; Francesco Pallone; Giovanni Monteleone
Journal:  World J Gastroenterol       Date:  2008-07-28       Impact factor: 5.742

4.  Retroviral cyclin enhances cyclin-dependent kinase-8 activity.

Authors:  Joel Rovnak; Connie D Brewster; Sandra L Quackenbush
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

5.  Role of microRNA 30a targeting insulin receptor substrate 2 in colorectal tumorigenesis.

Authors:  Qian Zhang; Qingchao Tang; Dandan Qin; Lei Yu; Rui Huang; Guixiang Lv; Zhaoxia Zou; Xiao-chen Jiang; Chendan Zou; Wei Liu; Jing Luo; Zhixun Zhao; Shan Muhammad; Guiyu Wang; Ying-gang Chen; Xishan Wang
Journal:  Mol Cell Biol       Date:  2015-01-12       Impact factor: 4.272

6.  Tumor-suppressive effects of CDK8 in endometrial cancer cells.

Authors:  Weiting Gu; Chenguang Wang; Weihua Li; Fu-Ning Hsu; Lifeng Tian; Jie Zhou; Cunzhong Yuan; Xiao-Jun Xie; Tao Jiang; Sankar Addya; Yanhong Tai; Beihua Kong; Jun-Yuan Ji
Journal:  Cell Cycle       Date:  2013-03-01       Impact factor: 4.534

7.  Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer.

Authors:  Alec C Kimmelman; Aram F Hezel; Andrew J Aguirre; Hongwu Zheng; Ji-Hye Paik; Haoqiang Ying; Gerald C Chu; Jean X Zhang; Ergun Sahin; Giminna Yeo; Aditya Ponugoti; Roustem Nabioullin; Scott Deroo; Shenghong Yang; Xiaoxu Wang; John P McGrath; Marina Protopopova; Elena Ivanova; Jianhua Zhang; Bin Feng; Ming S Tsao; Mark Redston; Alexei Protopopov; Yonghong Xiao; P Andrew Futreal; William C Hahn; David S Klimstra; Lynda Chin; Ronald A DePinho
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-02       Impact factor: 11.205

8.  A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis.

Authors:  J Odvody; T Vincent; M P Arrate; B Grieb; S Wang; J Garriga; G Lozano; T Iwakuma; D S Haines; C M Eischen
Journal:  Oncogene       Date:  2010-03-22       Impact factor: 9.867

9.  A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth.

Authors:  Hiroaki Mita; Minoru Toyota; Fumio Aoki; Hirofumi Akashi; Reo Maruyama; Yasushi Sasaki; Hiromu Suzuki; Masashi Idogawa; Lisa Kashima; Kazuyoshi Yanagihara; Masahiro Fujita; Masao Hosokawa; Masanobu Kusano; Sorin Vasile Sabau; Haruyuki Tatsumi; Kohzoh Imai; Yasuhisa Shinomura; Takashi Tokino
Journal:  BMC Cancer       Date:  2009-06-23       Impact factor: 4.430

10.  Response of the primary tumor in symptomatic and asymptomatic stage IV colorectal cancer to combined interventional endoscopy and palliative chemotherapy.

Authors:  Silke Cameron; Diana Hünerbein; Tümen Mansuroglu; Thomas Armbrust; Jens-Gerd Scharf; Harald Schwörer; László Füzesi; Giuliano Ramadori
Journal:  BMC Cancer       Date:  2009-07-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.